

# EXECUTIVE SUMMARY

REDEFINING mRNA MEDICINES



## TECHNOLOGY PLATFORM OVERVIEW



### Proprietary SNIM® RNA

#### Stabilized Non-Immunogenic mRNA ("SNIM")

Novel nucleotide modifications paired with optimization of key mRNA design elements



### Proprietary SNaP LNP

#### Stabilized NanoParticles ("SNaP")


Novel cationic lipidoid facilitates tissue-agnostic cell transfection and endosomal escape



### Proprietary Stabilizer

#### High performance with no LNP aggregation


Formulation facilitates nebulization, thermostability, physical stability and lyophilization




## EXCEPTIONAL THERMOSTABILITY FAR EXCEEDS COMPETITOR'S TECHNOLOGY

SNIM RNA is the first mRNA technology to be stably lyophilized and rehydrated after 12 months

### 4 days stability at 25°C




### >12 months of stability at 2-8°C via lyophilization




## UNPARALLELED LNP STABILITY DUE TO OPTIMIZED FORMULATION

Prevents shaking induced quality-loss commonly experienced in practice

### Particle size distribution WITHOUT optimized formulation



### Particle size distribution WITH optimized formulation



Platform capabilities overcome **key obstacles** of currently available mRNA and LNP technology

### SUPERIOR STABILITY

Proprietary stabilizer is **vibration resistant** and the SNaP LNP offers **stability at room temperature for 4 days**. Scalable lyophilization and rehydration **removes ultra-cold chain requirements**

### BEST-IN-CLASS NEBULIZATION

Stabilizer **prevents LNP aggregation** across relevant dose range leading to **4x lower inhalation time** relative to competitors and no risk of aggregate-related immunity

### POTENT DELIVERY

SNaP LNP delivers mRNA into the respiratory tract with **>300x efficiency** and **2x cargo-capacity** vs. competitors

### LOWER IMMUNOGENICITY

Proprietary SNIM RNA modifications have **11x lower immunogenicity** vs. competitors which is comparable to NIM modification

# EXECUTIVE SUMMARY



## REDEFINING mRNA MEDICINES

ENTERING CLINIC IN 2024 WITH LEAD CANDIDATE IN PCD

## ADDITIONAL PLATFORM HIGHLIGHTS



## NEAR-TERM MILESTONES OFFER MULTIPLE VALUE INFLECTION POINTS

Leadership team with 100+ years experience developing mRNA technologies

Lead indications in PCD and PAP entering clinic in 2024 and 2025

Opportunities for partnerships to provide non-dilutive financing

\$80.0M financing will provide cash runway until 2026

INDICATION / MODALITY      PROGRAM      DELIVERY      DISCOVERY      PRECLINICAL      NEXT MILESTONE

### RESPIRATORY RARE DISEASE

INDICATION / MODALITY	PROGRAM	DELIVERY	DISCOVERY	PRECLINICAL	NEXT MILESTONE
Primary Ciliary Dyskinesia ("PCD")	ETH42	Inhaled			CTA: 2Q/2024
	ETH43	Inhaled			DP: 2Q/2024
	ETH44	Inhaled			DP: 2Q/2024
Pulmonary Alveolar Proteinosis ("PAP")	ETH45	Inhaled			DP: 2Q/2024

### INFECTIOUS DISEASE

INDICATION / MODALITY	PROGRAM	DELIVERY	DISCOVERY	PRECLINICAL	NEXT MILESTONE
Viral Asthma Exacerbations	ETH47	Nasal/ Inhaled			CTA: 2Q/2023
Betacoronavirus family	ETH50	Intra-Muscular			DP: 4Q/2023
Triple-M Vaccine	ETH48	Nasal			DP: 1Q/2023

## MANAGEMENT TEAM

### PD DR. CARSTEN RUDOLPH

Chief Executive Officer

Inventor of SNIM RNA-Technology and author of >125 publications and numerous patents with deep expertise in mRNA and delivery. Awarded with the prestigious BioFuture Award in 2005.

### Prof. DR. CHRISTIAN PLANK

Chief Technology Officer

Inventor of Ethris LNP delivery technology and author of >170 publications and numerous patents in the field of nucleic acid delivery. Lecturer at the Technical University of Munich.

### DR. THOMAS LANGENICKEL

Chief Medical Officer

50+ INDs & CTAs filed in previous roles at Novartis and BMS with deep expertise in clinical development for respiratory, cardiovascular and metabolic diseases.

### DR. CHRISTIAN WAWRZINEK

Chief Corporate Strategy Officer

Serial entrepreneur & investor with deep expertise of scaling companies - >€1B revenue generated, EY Entrepreneur of the year, Deloitte Fast50 #1, Nasdaq-Nordic Reverse IPO.

### DR. CLIFF HOLLOWAY

Chief Business Officer

Experienced biotech executive with significant number of past deals ranging from tech partnerships, in/out-licensing, royalty agreements, co-developments, JVs, M&A and capital raising.

## FINANCING & PARTNERSHIPS

